Historical evolution and prospect of rifampicin-resistant tuberculosis prevention and control in China

doi:10.19982/j.issn.1000-6621.20240336

Abstract

Abstract:

Rifampicin-resistant tuberculosis (RR-TB) is a major public health problem facing in China. How to control and prevent drug-resistant tuberculosis and reduce its harm to society and the public, the author comprehensively reviewed the historical evolution of drug-resistant tuberculosis control and prevention in China from three stages: exploration and research, planning and implementation, and comprehensive promotion. From the exploration of nothing, to the innovative establishment of a new model for drug-resistant tuberculosis control and prevention and the results achieved. At the same time, in response to the challenges of high rifampicin-resistance rate with retreated patients and unsatisfactory treatment success rate of among patients undergoing treatment in China, the author also puts forward suggestions and prospects for the next steps for your reference.

Key words: Drug resistance, Tuberculosis, Rifampin, Universal precautions, Therapeutics

CLC Number:

Ruan Yunzhou, Su Wei, Zhang Hui, Zhao Yanlin. Historical evolution and prospect of rifampicin-resistant tuberculosis prevention and control in China[J]. Chinese Journal of Antituberculosis, 2024, 46(10): 1166-1170. doi: 10.19982/j.issn.1000-6621.20240336

References 18

[1]	关于结核病控制和患者治疗的北京“行动倡议”共同应对全球耐多药/广泛耐药结核病的流行. 中国防痨杂志, 2009, 31(5): 253-255.
[2]	Van Deun A, Decroo T, Piubello A, et al. Principles for constructing a tuberculosis treatment regimen: the role and definition of core and companion drugs. Int J Tuberc Lung Dis, 2018, 22(3): 239-245. doi:10.5588/ijtld.17.0660. pmid: 29471899
[3]	World Health Organization. Definitions and reporting framework for tuberculosis—2013 revision. Geneva: World Health Organization, 2013.
[4]	陈明亭, 李仁忠, 阮云洲. 耐多药结核病防治标准化培训教程. 北京: 人民卫生出版社, 2015: 8-9.
[5]	申丽君, 王艺曈, 李雪, 等. 基于疗程费用测算耐药结核病患者药物负担. 中国防痨杂志, 2019, 41(9): 962-967. doi:10.3969/j.issn.1000-6621.2019.09.010.
[6]	World Health Organization. Global tuberculosis report 2023. Geneva: World Health Organization, 2023.
[7]	中华人民共和国卫生部. 全国结核病耐药性基线调查报告(2007—2008年). 北京: 人民卫生出版社, 2010: 24-37.
[8]	王胜芬, 周杨, 欧喜超, 等. 我国结核病耐药状况: 2018年全国结核病耐药监测数据分析. 中国防痨杂志, 2022, 44(11): 1141-1147. doi:10.19982/j.issn.1000-6621.20220268.
[9]	World Health Organization.Global tuberculosis report 2020. Geneva: World Health Organization, 2020.
[10]	WHO declares tuberculosis a global emergency. Soz Praven-tivmed, 1993, 38(4): 251-252.
[11]	中华人民共和国卫生部新闻办公室. 卫生部印发全国结核病防治规划2006—2010年实施计划. 2016-01-18.
[12]	陈明亭, 李仁忠, 阮云洲, 等. 全球基金耐多药结核病控制项目在中国——成就与经验. 北京: 人民卫生出版社, 2015: 1-4.
[13]	Li R, Ruan Y, Sun Q, et al. Effect of a comprehensive programme to provide universal access to care for sputum-smear-positive multidrug-resistant tuberculosis in China: a before-and-after study. Lancet Glob Health, 2015, 3(4): e217-228. doi:10.1016/S2214-109X(15)70021-5.
[14]	王黎霞. 耐多药肺结核流行特征和治疗管理策略研究. 中国科技成果, 2015(20): 76, 78. doi:10.3772/j.issn.1009-5659.2015.20.037.
[15]	王黎霞, 李仁忠, 阮云洲, 等. 西部地区应用新技术发现耐多药结核病试点经验. 北京: 人民卫生出版社, 2018: 7-8.
[16]	周宇辉, 刘剑君. 创新结核病控制:中盖结核病项目三期典型实践. 北京: 人民卫生出版社, 2019: 7-11.
[17]	Ruan Y, Li L, Xu L, et al. Practical Experiences of Delivering Multidrug-Resistant Tuberculosis Comprehensive Supportive Care Services in China. China CDC Wkly, 2021, 3(26): 566-568. doi:10.46234/ccdcw2021.146.
[18]	李仁忠, 阮云洲, 苏伟. 提高耐药结核病发现水平实践. 北京: 人民卫生出版社, 2021: 2-9.